# A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

> **NCT05829226** · PHASE1 · COMPLETED · sponsor: **PureTech** · enrollment: 101 (actual)

## Conditions studied

- AML, Adult Recurrent
- MDS

## Interventions

- **DRUG:** LYT-200
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT05829226
- **Lead sponsor:** PureTech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-12
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05829226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05829226, "A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05829226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*